EventHealthAugust 21, 2026

Moderna/Merck AI-designed cancer vaccine passes Phase 3 trial

Read original source →x.com

Moderna and Merck's personalized mRNA cancer vaccine, intismeran autogene, met its primary endpoint in the 1,137-patient INTerpath-001 Phase 3 trial for resected stage IIB-IV melanoma. AI ranks up to 34 neoantigens per patient; Moderna stock surged over 110%.

How this story unfolded

8 days · 1 report · 7 community posts · from Aug 19

  1. Aug 19
  2. Aug 20
  3. Aug 21
  4. Aug 22
  5. Aug 27

More stories today

Open the live feed